Clinical trials

  • VRDN-003 for Thyroid eye disease
  • Esmolol hydrochloride for Liver cirrhosis|Type 2 diabetes mellitus|Antineoplastic-induced cardiotoxicity
  • MEXILETINE HYDROCHLORIDE for Non-dystrophic myotonias | Myotonia congenita | Paramyotonia congenita | Sodium channel myotonia
  • NIVOLUMAB for Gastric cancer|Metastatic gastric cancer
  • Avapritinib for Systemic mastocytosis
  • VENETOCLAX for Chronic myelomonocytic leukemia (higher‑risk CMML)
  • (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE for Pancreatic cancer | Bile duct cancer | Gastric cancer | Epithelial ovarian cancer
  • ALPELISIB for Hormone receptor-positive HER2-negative advanced breast cancer|PIK3CA-mutated breast cancer
  • VENETOCLAX for Myelodysplastic syndromes | Acute myeloid leukemia
  • Ustekinumab for Ulcerative colitis
  • AZACITIDINE for Myelodysplastic syndromes (higher-risk)
  • Daratumumab for Multiple myeloma with extramedullary disease|Multiple myeloma